The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
Abstract
INTRODUCTION: Inflammatory pathways may be an important contributor to morbidity and mortality associated with lung cancer. The oncogene-associated inflammatory microenvironment leads to production of inflammatory cytokines such as IL-6. IL-6 is associated with poor prognosis and correlates with debilitating lung-cancer-related symptoms such as fatigue, thromboembolism, cachexia and anemia. IL-6 has been implicated in resistance of lung cancer to EGF inhibitors. A mAb therapy targeting IL-6 may be an effective treatment for the inflammatory microenvironment in lung cancer. AREAS COVERED: An understanding of the inflammatory pathways involved in lung cancer, including the central role of IL-6, and how inflammation affects the course and treatment of lung cancer. The mAb ALD518, which targets IL-6, and its investigational development and use in advanced NSCLC. Preclinical and Phase I and II studies of ALD518 with a focus on NSCLC. How ALD518 could be used in NSCLC in the future. EXPERT OPINION: IL-6-mediated inflammation may contribute to NSCLC-related morbidity and mortality. In preclinical and Phase I and II trials ALD518 targeting IL-6 appears well tolerated and ameliorates NSCLC-related anemia and cachexia. Other clinical outcomes need further study, and may include effects on overall survival, hypercoagulability associated with lung cancer and decreased resistance to EGF-pathway inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Hepcidin—a regulator of intestinal iron absorption and iron recycling by macrophages
GANZ, T. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.08.020 · Cited by 393 · cited 1×
“Inflammation has been firmly linked to anemia through the upregulation of IL-6, leading to increased production of the iron regulatory peptide hepcidin resulting in iron sequestration by macrophages and decreased iron absorption from the gastrointestinal tract [15,16].”
BackgroundIron Sequestration and Anemia of Inflammation
Ganz, T., & Nemeth, E. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.06.001 · Cited by 361
Song, S.-N. J., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T., & Yoshizaki, K. (2010) · Blood · doi:10.1182/blood-2010-03-271791 · Cited by 228 · cited 1×
“In multicentric Castleman’s disease the anti IL-6 receptor antibody, tocilizumab has been shown to reduce hepcidin levels and improve survival [22].”
BackgroundIn anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2
Maes, K., Nemeth, E., Roodman, G. D., Huston, A., Esteve, F., Freytes, C., Callander, N., Katodritou, E., Tussing-Humphreys, L., Rivera, S., et al. (2010) · Blood · doi:10.1182/blood-2010-03-274571 · Cited by 132
Anemia in Hodgkin's Lymphoma: The Role of Interleukin-6 and Hepcidin
Hohaus, S., Massini, G., Giachelia, M., Vannata, B., Bozzoli, V., Cuccaro, A., D'Alo', F., Larocca, L. M., Raymakers, R. A. P., Swinkels, D. W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6873 · Cited by 110
Songür, N., Kuru, B., Kalkan, F., Özdilekcan, Ç., Çakmak, H., & Hızel, N. (2004) · Tumori Journal · doi:10.1177/030089160409000207 · Cited by 96
Linking anemia to inflammation and cancer: The crucial role of TNFα
Buck, I., Morceau, F., Grigorakaki, C., Dicato, M., & Diederich, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.12.018 · Cited by 66
Cited by
ESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114
Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
Fearon, K. C. H., Glass, D. J., & Guttridge, D. C. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.011 · Cited by 1,205
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Understanding the mechanisms and treatment options in cancer cachexia
Fearon, K., Arends, J., & Baracos, V. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.209 · Cited by 940
Metadata
- Authors
- Bayliss, T. J., Smith, J. T., Schuster, M., Dragnev, K. H., & Rigas, J. R.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2011-10-13
- Volume
- 11
- Issue
- 12
- Pages
- 1663-1668
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2028043263
- Cited by
- 243
- References
- 10
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. https://app.cochat.ai/papers/10.1517/14712598.2011.627850
- The paper
- Bayliss, T. J., Smith, J. T., Schuster, M., Dragnev, K. H., & Rigas, J. R. (2011). A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.2011.627850
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.